Hyaluronidase Power Injection Market Size & Share, by Source (Animal-Derived Hyaluronidase, Synthetic Hyaluronidase, Bio-Engineered Hyaluronidase); Application (Dermatology, Chemotherapy, Ophthalmology, Plastic Surgery, Cosmetology); Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5456
  • Published Date: Dec 13, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Hyaluronidase Power Injection Market size is expected to reach USD 2 Billion by the end of 2036, growing at a CAGR of over 9% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of hyaluronidase power injection was around USD 910 Million. The increasing acuteness across different application fields will act as the primary driver that will drive the market of hyaluronidase power injection and will take it to the anticipated CAGR. For instance, the degradation kinetics of the TEOSYAL RHA accumulation, manufactured by TEOXANE SA (Geneva, Switzerland), is implementing the maintained network technology (PNT) to use in different applications. In humans, six different hyaluronidases, HYAL1-4, HYAL-P1, and PH-20, have been identified. Hyaluronidase looks for applications in cosmetic therapies, cancer treatment, and ophthalmic therapeutic solutions.

Additionally, the increasing number of nominally invasive aesthetic surgeries is calculated to amplify the hyaluronidase power injection system's demand in the forecast period. For instance, The International Society of Aesthetic Plastic Surgery (ISAPS) announced the results of its yearly Global Survey on Aesthetic/Cosmetic Procedures this week at the ISAPS Olympiad Athens World Congress 2023, which rounded up more than 1,000 attendees from 90 countries to talk about the newest scientific research, novelties, and processes to modify patient protection in aesthetic plastic surgery. The report demonstrates an 11.2% complete rise in techniques executed by plastic surgeons in 2022 with more than 14.9 million surgical and 18.8 million non-surgical techniques executed across the world. Liposuction was the most general surgical technique in 2022 as in 2021, with more than 2.3 million techniques and a 21.1% rise.

Hyaluronidase Power Injections Market Size
Get more information on this report: Request Free Sample PDF

Hyaluronidase Power Injection Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~USD 910 Million

Forecast Year Market Size (2036)

~USD 2 Billion

Regional Scope

  • North America (North America, Canada, Mexico)
  • Europe (Germany, Spain, UK, France, Italy, Russia, Others)
  • Asia Pacific (Japan, China, India, Australia, Others)
  • Middle East and Africa (South Africa, UAE, Others)
  • Latin America (Brazil, Argentina, Others)


Get more information on this report: Request Free Sample PDF

Hyaluronidase Power Injection Sector: Growth Drivers and Challenges


Growth Drivers

  • Therapeutic Uses of Hyaluronidase Power Injection - Hyaluronidase has been utilized in medical usage for over 60 years. Internal hyaluronidases in the human body get physiological and pathophysiological importance because of their enzymatic activity at the time of the cleavage of hyaluronan. The possibility for therapeutic utilization of testicular and recombinant hyaluronidase has been even more recognized and modified in recent years. Most appropriate in practice is the co-application of hyaluronidase and other active materials to increase their bioavailability within the tissue. The US Food and Drug Administration has licensed hyaluronidase for symptoms like subcutaneous fluid infiltration (hypodermoclysis), as an accessory to accentuate the absorption and distribution of drugs in subcutaneous tissue or to maintain extravasation, and as an accessory to generate the absorption of contrast media in urinary tract angiography (subcutaneous urography).
  • Safer to Use in Surgeries to Increase the Absorption of Drugs - Several patients with chronic diseases need injections as part of their persistent medical treatment. Hyaluronidase has been demonstrated to enhance the systemic submission of injectable drugs and give better therapy results for these patients. Cases of recent drugs being implemented in amalgamation with hyaluronidase comprise but are not restricted to insulin in diabetes, beta interferons in multiple sclerosis, biotherapeutics in rheumatoid arthritis, immunoglobulin substitution treatment in basic immunodeficiencies, and monoclonal antibodies in cancer treatment. Hyaluronidase has recently been utilized for multiple other kinds of medical management as well. Ordinary administration of hyaluronidase is via hypodermic injection with doses starting from 50 to 300 units/mL. When implementing this enzyme to increase the dispersion of another pharmaceutical agent, the administration is feasible in one of two ways. It may be injected first into the hypodermic tissue, and then the second agent may be injected consecutively with the same needle. Or it may be co-directed with the other agent in a single injection.
  • Increase in Awareness of People About Their Beauty - Moreover, increasing concern associated with the conversion of physical images has taken to a rising need for cosmetics and aesthetic processes. The requirement for hyaluronidase around cosmetic dermatology is accelerating and is mainly propelled by the progress in the incidence of skin disorders and easy entrance to modified cosmetic therapies in different regions.


  • Several Side Effects of Excessive Hyaluronidase Power Injection - Quick hypersensitivity reactions caused by hyaluronidase are evident as erythematous edema after 1 to 2 hours, and there is no response to antibiotic treatment. In such cases, systemic steroids, antihistamines, and steroid cream applications are helpful. Postponed hypersensitivity reactions caused by hyaluronidase can appear even after 24 hours, and in such scenarios, a skin test will not generate a positive reaction within 20 minutes, aftermath in an adverse diagnosis. The most often faced side effects are injection site reaction, headache, fatigue, nausea, and fever. Serious reactions can comprise hypersensitivity reactions, anaphylaxis, hyperviscosity, and thromboembolism. Recombinant human hyaluronidase occurs with a black box warning of thrombosis. Animal-derived hyaluronidase is immunogenic and may create allergic reactions. Human recombinant hyaluronidase (rHuPH20) is better permitted and has less potential to create an allergic reaction. Roughly 6% of the population get anti-rHuPH20 antibodies that are non-neutralizing and get no clinically substantial results.
  • Lack of Trials and Tests of Hyaluronidase
  • Limitations in The Knowledge of People on How to Use Hyaluronidase Power Injection

Hyaluronidase Power Injection Segmentation

Source (Animal-Derived Hyaluronidase, Synthetic Hyaluronidase, Bio-Engineered Hyaluronidase)

The animal-derived hyaluronidase segment in the hyaluronidase power injection market is projected to hold its position with over 55% of revenue share by the end of the predicted timeline. It is because most licensed and advertised brands, at present, are taken from animal sources, and the most commonly implemented animal sources are bovine and porcine products. To illustrate, the US FDA has approved the recombinant human hyaluronidase PH20 (rHuPH20) which works locally to provisionally eliminate the glycosaminoglycan hyaluronan’s barrier, enabling quick subcutaneous (SC) submission of large volumes and/or high doses of successively or co-directed therapeutics. Moreover, the animal-derived hyaluronidase market has witnessed a substantial number of product approvals, contributing to the massive demand for the animal-derived hyaluronidase segment in the coming years.

Application (Dermatology, Chemotherapy, Ophthalmology, Plastic Surgery, Cosmetology)

Hyaluronidase power injection market from the dermatology segment held the largest profit share in 2023 and is estimated to hold this position with approximately 45% revenue share by the end of 2036. The increasing importance of hyaluronidase power injections’ safety in dermatology has resulted in the highest profit production. In December 2021, a research study released by the American Society for Dermatologic Surgery (ASDA) expressed that hyaluronic acid fillers VYC-20I were harmless and efficient for cheek augmentation via cannula and noninferior to needle injection.  Utilizing cannulas to provide facial fillers may limit negative events (AEs) in comparison with needle injection. The setup of a standard technique is anticipated to modify the momentum of market expansion in the future.

Our in-depth analysis of the global hyaluronidase power injection market includes the following segments:


  • Animal-Derived Hyaluronidase
  • Synthetic Hyaluronidase
  • Bio-Engineered Hyaluronidase


  • Dermatology
  • Chemotherapy
  • Ophthalmology
  • Plastic Surgery
  • Cosmetology

          Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Hyaluronidase Power Injection Industry - Regional Synopsis

North American Market Statistics

North American region is expected to account for 30% share of the global hyaluronidase power injection market by 2036. This is due to the increasing number of experimental procedures that present an in-vitro assessment of the biological attainability of hyaluronidase and the appearance of key players producing these products in the region. According to The American Society of Plastic Surgeons (ASPS), the globe's largest plastic surgery company, symbolizing 92 percent of all board-certified plastic surgeons in the United States data released in 2022, there were 26.2 million surgical and minimally invasive cosmetic and reconstructive techniques experimented as well as executed in the United States in 2022. More particularly, there has been a 19% surge in cosmetic surgery techniques since 2019. Moreover, the high adoption of progressed therapy choices and an acknowledgeable number of dermatology clinics advocating such therapies contribute to immense market expansion across North America.

APAC Market Analysis

Asia Pacific hyaluronidase power injection market is projected to expand at the quickest CAGR during the forecast period and is set to hold the position of second largest shareholder with almost 26% profit share. This growth is wheeled as a result of medical tourism for dermatology therapies and dermatological device applications in different countries of the region. In line with the Korea Health Industry Development Institute, the number of medical tourists exploring South Korea increased eightfold in ten years—from 60,000 in 2011 to almost half a million in 2021. Overseas patients now make up almost half of all plastic surgeries executed in South Korea. In addition, the presence of a significant number of suppliers together with the emergence of technologies in South Korea is further anticipated to drive the market expansion.

Research Nester
Hyaluronidase Power Injections Market
Get more information on this report: Request Free Sample PDF

Companies Dominating the Hyaluronidase Power Injection Market

    • Argenx SE
      • Company Overview
      • Business Planning
      • Main Product Offerings
      • Financial Execution
      • Main Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • PrimaPharma, Inc.,
    • Halozyme, Inc.
    • Bausch & Lomb Incorporated
    • The Cooper Companies Inc.,
    • Sun Pharmaceutical Industries Ltd.
    • STEMCELL Technologies Inc.
    • Shijiazhuang Yiang Technology Co., Ltd.
    • Calzyme
    • Dermax Medical Technology (Hebei) Co., Ltd.


In The News

  • Argenx SE, an international immunology organization that works to modify the lives of people with serious autoimmune diseases, reported affirmative topline information from the Phase 3 ADAPT-SC study testing subcutaneous (SC) efgartigimod (1000 mg efgartigimod-PH20) as a therapy for generalized myasthenia gravis (gMG). Argenx delivered a biologics approval application (BLA) to the US FDA.
  • The Food and Drug Administration (FDA) released a letter sanctioning the emergency utilization of the Alinity m Resp-4-Plex for the coexisting qualitative detection and distinction of RNA from SARS-CoV-2, influenza A virus (flu A), influenza B virus (flu B), and/or Respiratory Syncytial Virus (RSV) in anterior nasal or nasopharyngeal swab specimens accumulated by a healthcare provider (HCP).

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5456
  • Published Date: Dec 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing sharpness across various application fields will majorly drive the market growth of the hyaluronidase power injection market.

The market size of the hyaluronidase power injection market is expected to get a CAGR of approximately 9% over the forecast period, i.e., 2024-2036.

The major players in the market are PrimaPharma, Inc., Halozyme, Inc., Bausch & Lomb Incorporated, The Cooper Companies Inc., Sun Pharmaceutical Industries Ltd., STEMCELL Technologies Inc., Shijiazhuang Yiang Technology Co., Ltd., Calzyme, Dermax Medical Technology (Hebei) Co., Ltd., Takeda Pharmaceuticals Co Limited, Janssen Global Services, LLC, Astellas Pharma Inc., Seagen Inc.

The animal-derived hyaluronidase segment is anticipated to reap the largest market size with almost 55% by the end of 2036 and demonstrate substantial growth scopes.

The market in the North American region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.
Hyaluronidase Power Injection Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying